

TYKKTARM




Polypp: frembukning fra overflaten
2/3 er adenomatøse- **premaligne**

Ofte asymptomatiske / mulig blødning

2003 Estimated US Cancer Cases*

	Men 675,300	Women 658,800	
Prostate	222,849		210,816 Breast
Lung/bronchus	94,542		79,056 Lung/bronchus
Colon/rectum	74,283		72,468 Colon & rectum
Urinary bladder	40,518		39,528 Uterine corpus
Melanoma of skin	27,012		26,352 Ovary
Non-Hodgkin lymphoma	27,012		26,352 Non-Hodgkin lymphoma
Kidney	20,259		19,764 Melanoma of skin
Oral cavity	20,259		19,764 Thyroid
Leukemia	20,259		13,176 Pancreas
Pancreas	13,506		13,176 Urinary bladder
All other sites	114,801		62,238 All other sites




ONS=Other nervous system.
*Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.
Source: American Cancer Society, 2003.



2003 Estimated US Cancer Deaths*


	Men 285,900	Women 270,600	
Lung/bronchus	88,629		67,650 Lung/bronchus
Prostate	28,590		40,590 Breast
Colon & rectum	28,590		29,766 Colon & rectum
Pancreas	14,295		16,236 Pancreas
Non-Hodgkin lymphoma	11,436		13,530 Ovary
Leukemia	11,436		10,824 Non-Hodgkin lymphoma
Esophagus	11,436		10,824 Leukemia
Liver/intrahepatic bile duct	8,577		8,118 Uterine corpus
Urinary bladder	8,577		5,412 Brain/ONS
Kidney	8,577		5,412 Multiple myeloma
All other sites	62,898		62,238 All other sites



ONS=Other nervous system.
*Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.
Source: American Cancer Society, 2003.



TYKKTARM CANCER






Figure 120-1 Age-standardized incidence of colon cancer per 100,000 population worldwide for men (A) and women (B). (A and B, Data from Parkin DM, Whelen SL, Ferlay J, et al: Cancer Incidence in Five Continents. [IARC Sci. Publ. No. 143]. Series. Lyon, International Agency for Research on Cancer, 1997.)

Screening Techniques for Colorectal Cancer

- Fecal occult blood test (FOBT) every year, or
- Flexible sigmoidoscopy every 5 years, or
- A fecal occult blood test every year plus flexible sigmoidoscopy every 5 years (*recommended by the American Cancer Society*), or
- Double-contrast barium enema every 5 to 10 years, or
- Colonoscopy every 10 years (*recommended by the American College of Gastroenterology*).



Screening For Colon Cancer SAVES LIVES!!!

Test	Mortality Reduction
Fecal occult blood testing	33%
Flexible sigmoidoscopy (in portion of colon examined)	66%
FOBT + flexible sigmoidoscopy (compared to sigmoidoscopy alone)	43%
Colonoscopy (after initial screening and polypectomy)	~76-90%

Table 46.4. **GUIDELINES FOR COLORECTAL CANCER SCREENING***

Asymptomatic men or women beginning at age 50 years should undergo screening with one or more of the following:

- Annual fecal occult blood test,
- Flexible sigmoidoscopy every 5 years, or
- Double-contrast barium enema every 5 to 10 years, or
- Colonoscopy every 10 years

Diagnostic evaluation with colonoscopy or double-contrast barium enema (preferably accompanied by flexible sigmoidoscopy) should be performed in any patients with either positive findings on screening with fecal occult blood testing or symptoms suggestive of colorectal cancer or polyps.

*Endorsed by the American Cancer Society, American College of Gastroenterology, American Society of Colon and Rectal Surgeons, American Society for Gastrointestinal Endoscopy, Oncology Nursing Society, and Society of American Gastrointestinal Endoscopic Surgeons.

**Table 46.1. CLINICAL RISK FACTORS
FOR COLORECTAL CANCER**

GENETIC

Polyposis syndromes

Familial polyposis coli
Gardner's syndrome
Turcot syndrome (CNS tumors)
Oldfield's syndrome (sebaceous cysts)
Peutz-Jeghers syndrome (hamartomas)

Nonpolyposis syndromes

Lynch syndrome I
Lynch syndrome II (associated extracolonic cancers)

Preexisting disease


Ulcerative colitis
Crohn's disease
Prior colorectal cancer
Neoplastic polyps
Pelvic irradiation
Breast or genital tract cancer

GENERAL

Age >40 y
Family history of colorectal cancer



ØNSKE OM UNDERSØKELSE !





MÅ UTFØRES RIKTIG !

MÅ HA KOMPETANSE !



Colonoskopi – oppdager og
fjerner polypper !

MEN MISTER:


”To X endoskopi, samme dag:
mister ca. 25% av adenomer < 5mm
5% >1 cm.”





? !

Hva er dette?
Hva skal jeg gjøre?



• **Klassifisering av polypper:**

Neoplastisk

- Adenomer
- Tubulær
- Tubulovilløs
- Villøs
- Serrated adenom
- (Flat adenoma)
-

Ikke- neoplastisk

- Hyperplastisk
- Inflammatorisk (pseudopolypp)
- Mucosal prolaps syndrome
-
- Hamartom
-

Submukosal

- Neoplastisk
- Lymfoid Leiomyomatøs Lipomatøs Neurofibrom Ganglioneurom
- Granulærcelle tumor (-myoblastom)
- Ikke- neoplastisk Heterotopisk gastric mucosa
- Hamartom Vaskulært Cowden`s syndrome (multiple hamartom)
-

Polyposis syndrome <1%

Neoplastic polyps (adenomas)

- Sporadic polyps
- Multiple adenomas (FAP, AFAP, MYH)

Non-neoplastic polyps

Post- inflammatorisk polypp Fibroblastic polypp
Cap- polypp Diverticular polypp of colon


Juvenil polypp (isolerte polypper)
Peutz- Jeghers polypp (solitær)

Gastrointestinal polypose syndrome

-
- Hereditær polypose syndrome
 - Adenomer
 - Familiær adenomatøs polyposis coli (FAP)
 - Attenuated ----"---- (AFAP)
 - Gardner`s syndrome
 - Turcot`s syndrome
 - MYH adenomatøs polyposis coli
 - Hamartomatøs
 - Peutz- Jegers syndrome
 - Juvenil polyposis syndrome (> 5 polypper)
 - Cowden`s sykdom
 - Bannayan- Riley- Ruvalcaba syndrome
 - Devon familie syndrome
 - Andre
 - Hereditær blandet polypose syndrome
 - Neurofibromatose, Type 1
 - Multiple endokrin neoplasi, Type 2
- Ikke hereditær polypose syndrome
 - Hyperplastisk polypose
 - Cronkhite- Canada syndrome (Hamartomatøs)
 - Lymfomatøs polypose
 - Nodulær lymfoid hyperplasi
 - Pneumatosis cystoides intestinalis
 - Colitis cystica profunda

Polypp:

- 2/3 av polyppene er adenomatøse
- Er dysplastiske: Har malignitetspotensiale
- Colorectal cancer utgår stort sett fra adenom
- Adenom til cancer: 7- 8 år
- 30- 40% av personer over 50 år: >1 adenom






Polypbase

- Sessile- base mot colonvegg
- Pedunkulert- stilk mellom basis og polyp
- Frembukende
- (Flat)
- (Nedsunket)

Celleatypi:

- Lavgradig: lett og moderat
- Høygradig: grov
- Grov: ((Carcinoma in situ = intramucosalt adenokarsinom))





NEOPLASTISK

Adenomatøse polypper

Histologisk arkitektur:



- Tubulært adenom
 - Tubulovilløst adenom
 - Villøst adenom
-
- Atypigrad

- Tubulært adenom
- 80% av adenomene
- Tubulær komponent >80%
- Histologiske trekk og polyppstørrelse viser malignitetspotensiale






LETT

MODERAT



GROV DYSPLASI




Villøst adenom:

- 5-15 %
- Villøs komponent, histologisk $>75\%$
- Ofte eldre personer
- Ofte ikke stilk
- Villøs- større risk for
cancer




Villøst adenom




Tubulovilløst adenom

- 5-15 % av adenomene
- Villøs komponent: 26- 75 %




Flat adenom, nedsunket type



Serrated adenoma

”Blandet hyperplastisk og adenomatøs polyppvekst”




ADENOMER

Negative faktorer- malign:

- Villøs
- Større
- Høygradig, histologisk

Invasiv malignitet: gjennom muscularis mucosa





Adenom med
pseudoinvasjon

IKKE- NEOPLASTISK


Hyperplastisk polypp

- Hyppig (30- 50 % i befolkningen)
- Ofte små (<5 mm)
- Ikke histologisk dysplasi
- Skopi- kan ikke skille fra adenom!
- (Stor (>2 cm.) mulig lett malignitetsrisk)

Hyperplastisk polypp





Inflammatorisk polypp




Juvenil Polypp

- Ofte < 5 år
- 80% i rektum
- Hamartomatøse
- Rik lamina propria og dilaterte cystiske kjertler
 - (Istedenfor økt antall av epiteliale celler)
- DD: Inflammatorisk polypp

Juvenil colon polypp




Pseudopolypper ved IBD



Colitis polyposa, ulcerativ colitt




Inflammatorisk polypp i ulcerativ colitt





Inflammatory cap polyp

Kappe av granulasjonsvev




Mucosal prolapse syndrome

Solitary rectal ulcer




Inflammatory myoglandulær polyp




SUBMUKOSALE POLYPPER

- Lymfoide aggregater
- Lipom
- Leiomyom
- Hemangiom
- Fibrom
- Carsinoid
- Pneumatosis cystoid intestinalis
- Metastase


Benign lymphoid hyperplasi




Polypoid lipom




Polypoid leiomyom i muskularis mucosae




Vaskulært hamartom




Neurofibrom





Ganglioneurom




S 100, immun.



Polypoid granular cell tumour



Endometriose





PNEUMATOSIS INTESTINALIS

Polyposis syndrome



Familiær Adenomatøs Polyposis (FAP)

- Autosomal dominant
- 100- 1000-- adenomer
- Økt risk for å utvikle colorectal cancer
- I noen familier- mave cancer
- Mutasjon i APC (adenomatøs polyposis recti) gen (Mangel på APC: cellemigrasjon , adhesjon (her minker)/ ATP passer på celleproliferasjon (her øker))

ATTENUATED FAP (Hereditær flat adenoma syndrome)

Familiær polypose coli (Familiær adenomatøs polypose)



Peutz- Jeghers syndrome

- (autosomal dominant)
- Polypper i tynntarm (alle), colon og rectum
- Non- gastrointestinal cancer
- Melanin flekk i kinnmukosa / leppe
- Hamartom
- Cumulative cancer risk på ca. 50 percent ved alder 60 år
- Oppfølging årlig



PEUTZ- JEGHERS SYNDROM






Figure 16-6

DIAGRAMMATIC REPRESENTATION OF THE NEOPLASMS ASSOCIATED WITH PEUTZ-JEGHERS SYNDROME

PEUTZ- JEGHERS SYNDROME



JUVENILE POLYPOSIS SYNDROME




Figure 16-13

DIAGRAMMATIC REPRESENTATION OF SOME OF THE LESIONS ASSOCIATED WITH JUVENILE POLYPOSIS SYNDROME

Cowden`s syndrome

(Multiple hamartom syndrome)

- Autosomal dominant
- Hamartomer

COWDEN'S SYNDROME




Figure 16-14

DIAGRAMMATIC REPRESENTATION OF MAJOR LESIONS DEVELOPING IN COWDEN'S SYNDROME

Cowden's syndrome



CRONKHITE- CANADA SYNDROME






Figure 16-20

DIAGRAMMATIC SUMMARY OF SOME OF THE LESIONS ASSOCIATED WITH CRONKHITE-CANADA SYNDROME



Cronkhite-Canada syndrome



"GJØR DET SELV"



Table 1 Staging Systems for Colon and Rectal Cancer

TUMOR DESCRIPTION	DUKES	MAC*	AJCC/UICC TNM	STAGE
Confined to mucosa	—	—	Tis	0
Invasion into submucosa	—	A	T1, N0, M0	I
Into muscularis propria	A	B1	T2, N0, M0	I
Involvement of serosa	B	B2	T3, N0, M0	II
Invasion of adjacent structure	—	B3*	T4, N0, M0	II
Positive LN, partial wall invasion	—	C1	—	—
Positive LN, transmural invasion	C	C2	Any T, N1-3, M0	III
Positive LN, adjacent organ invasion	—	C3*	—	—
Distant metastasis	D†	D	Any T or N, M1	IV

AJCC, American Joint Committee on Cancer; LN, lymph node; MAC, Modified Astler-Coller; N1, one to three adjacent lymph nodes involved; N2, four nodes near bowel involved; N3, any nodal metastasis along named vascular trunk; UICC, Union Internationale Centre le Cancer.

*Gunderson-Sosin system has the additional modification of B3 and C3 stages.

†Stage D not part of original 1932 Dukes' system, added later.




Figure 46.6. Schematic description of the staging systems with respect to depth of invasion.